Royalty Report: Cancer, Drugs, Medical – Collection: 266679


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Cancer
  • Drugs
  • Medical
  • Drug Discovery
  • Supply
  • Tissue
  • Therapeutic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 266679

License Grant
Licensor grants a worldwide exclusive license, with the right to assign or sublicense, to Licensors interest in any and all Joint Program IP and Program Information to allow Licensee to develop, market, promote, make, use, sell and import Compounds or Products or for any other purpose.

This research and collaboration agreement is to analyze and assess the potential clinical utility of certain compounds owned or licensed by Licensee.

License Property
Licensors IP means all Intellectual Property owned or Controlled by Licensor relating to Licensors  Biomerk Tumorgraftâ„¢ preclinical models.

Product means a preparation containing a Verified Compound having at least one indication for which Success has been predicted by Licensor under the Program.

Field of Use
The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology in conjunction with related services to offer solutions for two customer groups

Our Personalized Oncology Solutions (“POS) business which provides services to physicians and patients looking for information to help guide the development of a personalized treatment plans.

Our Translational Oncology Solutions (“TOS) business, which provides services to pharmaceutical and biotech companies seeking personalized approaches to drug development that will lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs.

Our technology platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. Our process technology involves the

implantation of human tumor fragments in immune compromised mice;

expansion of the original human tumor into a larger colony of mice through the passage of the tumor to subsequent generations of mice;

treatment of the implanted mice with oncology drugs;

measurement of tumor growth inhibition in treated mice relative to a control group of mice to determine the response of the tumor to the drug.

Our process is used for our POS business to test numerous drugs or drug combinations against a single patient’s tumor to determine which therapy results in the most efficacious response from the tumor.

IPSCIO Record ID: 276094

License Grant
The Company contracts with third-party vendors to license tumor samples for development into PDX models and use in the business.
License Property
PDX models means Patient Derived XenoGrafts.

The patient data and molecular information associated with these tumors, are referred to as “TumorGrafts” or “Patient Derived XenoGrafts” or “PDX Models”.

Our clinical trial simulation platform consists of processes, physical tumors, and information that we use to personalize the development and use of oncology drugs.

Patient derived xenografts are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse.

Field of Use
TumorGrafts® PDX models provide patients and physicians with a predictive model for how the patient's tumor will react to various anticancer drugs and treatments.

PDX models mimic the unique make-up of an individual’s tumor and may help guide the most effective treatment.

IPSCIO Record ID: 415

License Grant
The Company acquired the intellectual property rights relating to certain combination immunogene therapy technology from Licensor, an individual.
License Property
The technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025.  The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells.  The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF.  Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 67226

License Grant
In August 2005, the original Licensor entered into a collaboration with the Licensee to humanize the Licensors Sphingomab monoclonal antibody.  In 2014,  the original Licensors rights and obligations pursuant to the Agreement with the Licensee were transferred to the new Licensor, by means of a Deed of Novation. The drug is for the treatment of cancer, as a second-line therapy to treat patients with locally advanced, recurrent cancer.
License Property
Humanization under this agreement with the original Licensor involves utilizing proprietary processes for the purpose of modifying Sphingomab antibodies originally contained in mice for potential human acceptance in a clinical trial. The humanized version of Sphingomab that was produced from the collaboration is called Sonepcizumab.
Field of Use
The Licensee could owe the new Licensor certain additional contingent amounts when drug candidates based on Sonepcizumab pass through the levels of the FDA drug review and approval process.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.